Novel antiphospholipid antibodies in autoimmune bullous diseases

Lior Sagi, Sharon Baum, Ori Barzilai, Maya Ram, Nicola Bizzaro, Marielle Sanmarco, Yehuda Shoenfeld, Yaniv Sherer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Pemphigus and bullous pemphigoid are two autoimmune diseases that have similar pathogenesis. Both have a genetic predisposition, which promotes the production of auto antibodies targeted against different components of the epidermal desmosome and hemidesmosome. Antiphospholipid antibodies (aPL) are heterogeneous group of antibodies found in patients with autoimmune diseases and inflammatory conditions and are associated with thrombotic events. OBJECTIVE: We sought to determine the expression profile of eight non classical aPLs in ABD patients. METHODS: A cohort of 266 serum samples of patients with pemphigus, bullous pemphigoid and controls was screened for the presence of eight aPL antibodies, using the Bio-Rad BioPlex™ 2200 system. RESULTS: Phosphatidylserine-beta-2-glycoprotein-I (aPS-β2GPI) and anti prothrombin complex (aPT-PT) serum profiles were significantly more prevalent among ABD patients; 20.7% patients with ABD compared to 5.9% of control patients were positive for aPS-β2GPI IgM. In addition, aPT-PT IgM was more prevalent among ABD patients (31% vs. 14.8%). CONCLUSION: aPL auto antibodies are more prevalent in ABD. Any clinical association should be further determined.

Original languageEnglish
Pages (from-to)27-30
Number of pages4
JournalHuman Antibodies
Issue number1-2
StatePublished - 2015


  • Autoimmunity
  • antiphospholipid antibodies
  • autoantibodies
  • bullous pemphigoid
  • pemphigus


Dive into the research topics of 'Novel antiphospholipid antibodies in autoimmune bullous diseases'. Together they form a unique fingerprint.

Cite this